Cargando…
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Platinum drugs are heavily used first‐line chemotherapeutic agents for many solid tumours and have stimulated substantial interest in the biological activity of DNA‐binding metal complexes. These complexes generate DNA lesions which trigger the activation of DNA damage response (DDR) pathways that a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754470/ https://www.ncbi.nlm.nih.gov/pubmed/32812709 http://dx.doi.org/10.1002/cmdc.202000391 |